Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
cancer therapy
checkpoint inhibitor
immunotherapy
monoclonal antibody
Journal
Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489
Informations de publication
Date de publication:
21 Oct 2019
21 Oct 2019
Historique:
received:
24
09
2019
revised:
15
10
2019
accepted:
16
10
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
24
10
2019
Statut:
epublish
Résumé
Recently, modulation of immune checkpoints has risen to prominence as a means to treat a number of solid malignancies, given the durable response seen in many patients and improved side effect profile compared to conventional chemotherapeutic agents. Several classes of immune checkpoint modulators have been developed. Here, we review current monoclonal antibodies directed against immune checkpoints that are employed in practice today. We discuss the history, mechanism, indications, and clinical data for each class of therapies. Furthermore, we review the challenges to durable tumor responses that are seen in some patients and discuss possible interventions to circumvent these barriers.
Identifiants
pubmed: 31640266
pii: antib8040051
doi: 10.3390/antib8040051
pmc: PMC6963985
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Immunol. 2011 Nov 1;187(9):4403-9
pubmed: 22013206
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Nat Rev Immunol. 2004 Jun;4(6):420-31
pubmed: 15173831
Cell Res. 2018 Apr;28(4):416-432
pubmed: 29472691
Lancet Oncol. 2018 Nov;19(11):1468-1479
pubmed: 30262187
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a002436
pubmed: 20534709
Clin Cancer Res. 2009 Jan 1;15(1):390-9
pubmed: 19118070
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Oncoimmunology. 2012 Oct 1;1(7):1135-1145
pubmed: 23170260
JAMA Oncol. 2019 Apr 01;5(4):546-550
pubmed: 30570649
Front Immunol. 2018 Apr 26;9:866
pubmed: 29755464
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Nat Rev Immunol. 2010 Aug;10(8):554-67
pubmed: 20616810
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
J Clin Oncol. 2013 Feb 10;31(5):616-22
pubmed: 23295794
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
Ann Oncol. 2013 Jul;24(7):1813-1821
pubmed: 23535954
Eur J Immunol. 1994 Dec;24(12):3216-21
pubmed: 7805750
J Clin Oncol. 2012 Jun 10;30(17):2046-54
pubmed: 22547592
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Cancer Immunol Immunother. 2012 Feb;61(2):223-230
pubmed: 22065047
Lancet Oncol. 2017 Sep;18(9):1261-1273
pubmed: 28729154
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3740-5
pubmed: 16501042
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
J Leukoc Biol. 2000 Jan;67(1):2-17
pubmed: 10647992
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
J Clin Oncol. 2019 Mar 20;37(9):693-702
pubmed: 30726175
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
Nat Commun. 2016 Oct 31;7:13354
pubmed: 27796306
Cancer Cell. 2018 Apr 9;33(4):649-663.e4
pubmed: 29576375
Sci Rep. 2017 Jul 17;7(1):5532
pubmed: 28717238
ESMO Open. 2019 Jun 12;4(Suppl 3):e000510
pubmed: 31275618
Front Immunol. 2018 Aug 31;9:1977
pubmed: 30233579
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Immunother Cancer. 2016 Jun 21;4:38
pubmed: 27330811
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Semin Oncol. 2017 Apr;44(2):136-140
pubmed: 28923212
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Oncotarget. 2017 May 19;8(40):67129-67139
pubmed: 28978021
Blood. 2008 Aug 15;112(4):1175-83
pubmed: 18523152
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Clin Cancer Res. 2013 Nov 15;19(22):6286-95
pubmed: 23983255
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Lancet Oncol. 2017 Apr;18(4):446-453
pubmed: 28223062
Lancet Respir Med. 2015 Apr;3(4):301-9
pubmed: 25819643
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cancer Immunol Res. 2014 Feb;2(2):142-53
pubmed: 24778278
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
Immunotherapy. 2019 Apr;11(5):429-441
pubmed: 30698054
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Immunol Res. 2014 Sep;2(9):846-56
pubmed: 24872026
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
J Exp Med. 2009 Jun 8;206(6):1327-37
pubmed: 19451266
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
J Clin Oncol. 2017 Oct 20;35(30):3449-3457
pubmed: 28854067
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Immunol Res. 2011 Dec;51(2-3):170-82
pubmed: 22139852
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Immunotherapy. 2012 Dec;4(12):1795-8
pubmed: 23240746
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Eur J Cancer. 2017 Mar;74:55-72
pubmed: 28335888
Ann Oncol. 2013 Jan;24(1):75-83
pubmed: 22858559
J Immunol. 2005 May 1;174(9):5215-23
pubmed: 15843517
Clin Cancer Res. 2013 Jan 15;19(2):393-403
pubmed: 23204132
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Am J Pathol. 2003 Oct;163(4):1233-43
pubmed: 14507633
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Front Oncol. 2015 Feb 16;5:34
pubmed: 25763356
Mol Immunol. 2017 Mar;83:13-22
pubmed: 28092803
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Cancer Res. 2013 Dec 15;73(24):7189-7198
pubmed: 24177180
Clin Cancer Res. 2014 Dec 15;20(24):6593-604
pubmed: 25294904
Lancet Oncol. 2019 May;20(5):711-718
pubmed: 30922731
Nature. 1987 Jul 16-22;328(6127):267-70
pubmed: 3496540
Adv Immunol. 2000;74:181-273
pubmed: 10605607
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Clin Oncol. 2017 Dec 20;35(36):4050-4056
pubmed: 28837405
Cell. 2018 Aug 9;174(4):1031-1032
pubmed: 30096300
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Onco Targets Ther. 2018 Oct 16;11:7005-7009
pubmed: 30410357
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238
pubmed: 30054281
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
Curr Opin Immunol. 2011 Feb;23(1):146-52
pubmed: 20970973
Eur J Cancer. 2017 Nov;86:358-363
pubmed: 29100190
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Clin Oncol. 2016 Nov 1;34(31):3740-3748
pubmed: 27458307
J Immunol. 2012 Jan 1;188(1):21-8
pubmed: 22187483
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
J Immunother. 2007 Apr;30(3):251-60
pubmed: 17414316
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Clin Cancer Res. 2016 Mar 15;22(6):1364-70
pubmed: 26534966
Nat Med. 2019 Jun;25(6):929-935
pubmed: 31171876
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
J Exp Med. 2006 Apr 17;203(4):871-81
pubmed: 16606666
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936